BioMarin Pharmaceutical I...

58.67
-0.50 (-0.85%)
At close: Apr 21, 2025, 3:59 PM
58.79
0.20%
Pre-market: Apr 22, 2025, 04:24 AM EDT

BioMarin Pharmaceutical Statistics

Share Statistics

BioMarin Pharmaceutical has 191.75M shares outstanding. The number of shares has increased by 0.47% in one year.

Shares Outstanding 191.75M
Shares Change (YoY) 0.47%
Shares Change (QoQ) 0.1%
Owned by Institutions (%) 96.17%
Shares Floating 189.25M
Failed to Deliver (FTD) Shares 33
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 4.69M, so 2.46% of the outstanding shares have been sold short.

Short Interest 4.69M
Short % of Shares Out 2.46%
Short % of Float 2.47%
Short Ratio (days to cover) 3.07

Valuation Ratios

The PE ratio is 29.26 and the forward PE ratio is 14.33. BioMarin Pharmaceutical's PEG ratio is 0.21.

PE Ratio 29.26
Forward PE 14.33
PS Ratio 4.38
Forward PS 2.7
PB Ratio 2.21
P/FCF Ratio 26.27
PEG Ratio 0.21
Financial Ratio History

Enterprise Valuation

BioMarin Pharmaceutical has an Enterprise Value (EV) of 12.15B.

EV / Sales 4.26
EV / EBITDA 18.68
EV / EBIT 21.21
EV / FCF 25.56

Financial Position

The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.11.

Current Ratio 5.33
Quick Ratio 3.29
Debt / Equity 0.11
Debt / EBITDA 0.93
Debt / FCF 1.27
Interest Coverage 39.24

Financial Efficiency

Return on Equity is 7.54% and Return on Invested Capital is 5.97%.

Return on Equity 7.54%
Return on Assets 6.11%
Return on Invested Capital 5.97%
Revenue Per Employee $938.79K
Profits Per Employee $140.41K
Employee Count 3,040
Asset Turnover 0.41
Inventory Turnover 0.47

Taxes

Income Tax 114.9M
Effective Tax Rate 21.21%

Stock Price Statistics

The stock price has increased by -34.44% in the last 52 weeks. The beta is 0.3, so BioMarin Pharmaceutical's price volatility has been higher than the market average.

Beta 0.3
52-Week Price Change -34.44%
50-Day Moving Average 66.94
200-Day Moving Average 71.78
Relative Strength Index (RSI) 36.65
Average Volume (20 Days) 1.67M

Income Statement

In the last 12 months, BioMarin Pharmaceutical had revenue of 2.85B and earned 426.86M in profits. Earnings per share was 2.13.

Revenue 2.85B
Gross Profit 2.27B
Operating Income 484.21M
Net Income 426.86M
EBITDA 650.53M
EBIT 554.1M
Earnings Per Share (EPS) 2.13
Full Income Statement

Balance Sheet

The company has 942.84M in cash and 602.71M in debt, giving a net cash position of 340.13M.

Cash & Cash Equivalents 942.84M
Total Debt 602.71M
Net Cash 340.13M
Retained Earnings -194.69M
Total Assets 6.99B
Working Capital 2.63B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 572.84M and capital expenditures -85.42M, giving a free cash flow of 475.42M.

Operating Cash Flow 572.84M
Capital Expenditures -85.42M
Free Cash Flow 475.42M
FCF Per Share 2.5
Full Cash Flow Statement

Margins

Gross margin is 79.67%, with operating and profit margins of 16.97% and 14.96%.

Gross Margin 79.67%
Operating Margin 16.97%
Pretax Margin 18.98%
Profit Margin 14.96%
EBITDA Margin 22.79%
EBIT Margin 16.97%
FCF Margin 16.66%

Dividends & Yields

BMRN does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 3.42%
FCF Yield 3.81%
Dividend Details

Analyst Forecast

The average price target for BMRN is $90, which is 53.4% higher than the current price. The consensus rating is "Buy".

Price Target $90
Price Target Difference 53.4%
Analyst Consensus Buy
Analyst Count 22
Stock Forecasts

Scores

Altman Z-Score 6.2
Piotroski F-Score 6